first
vaccin
similar
earli
pneumococc
vaccin
base
polysaccharid
incap
provok
memori
bcell
respons
failur
polysaccharid
vaccin
protein
conjug
h
influenza
vaccin
introduc
prove
much
effect
vaccin
conjug
least
four
differ
carrier
protein
develop
prpt
hboc
prpomp
prpd
prpt
seem
one
immunogen
becom
wide
use
vaccin
prpd
longer
use
children
poor
immunogenc
h
influenza
type
b
hib
vaccin
may
administ
separ
combin
vaccin
carriag
type
b
h
influenza
reduc
vaccin
individu
reduct
carriag
provid
degre
herd
immun
nonvaccin
children
lower
risk
come
contact
organ
expos
mainli
vaccin
person
epidemiolog
basi
sinc
introduct
conjug
hib
vaccin
develop
countri
incid
seriou
infect
due
type
b
h
influenza
declin
sharpli
overal
result
random
trial
demonstr
reduct
invas
diseas
caus
pathogen
note
effect
confirm
epidemiolog
surveil
demonstr
virtual
elimin
invas
diseas
type
b
h
influenza
mani
part
usa
vaccin
quit
safe
associ
minor
advers
effect
adult
seriou
infect
caus
nontyp
h
influenza
vaccin
pathogen
prove
much
difficult
present
although
sever
candid
vaccin
preclin
trial
none
shown
signific
promis
realiti
effect
vaccin
nontyp
infect
remain
futur
vaccin
prepar
weaken
kill
virus
viral
subunit
trigger
specif
protect
immun
vaccin
singl
effect
tool
prevent
communic
diseas
highlight
achiev
smallpox
poliomyel
erad
program
rise
infect
effect
vaccin
avail
human
immunodefici
viru
malaria
worm
tuberculosi
world
health
organ
initi
target
acut
respiratori
diseas
infanc
earli
childhood
novel
immun
approach
effect
vaccin
need
urgent
viral
respiratori
diseas
progress
disappointingli
slow
vaccin
candid
often
show
reduc
efficaci
infanc
partial
immun
adult
immunocompromis
elderli
howev
sever
promis
vaccin
clinic
trial
like
vaccin
respiratori
syncyti
viru
parainfluenza
licens
within
next
year
mucos
deliv
influenza
vaccin
avail
novel
adjuv
offer
prospect
better
immunogen
ideal
multival
mucos
vaccin
develop
provid
protect
spectrum
respiratori
infect
specif
target
age
group
abil
grow
virus
egg
tissu
cultur
allow
develop
live
kill
viral
vaccin
current
use
kill
whole
viru
influenza
vaccin
introduc
vaccin
measl
mump
rubella
came
soon
world
war
ii
contribut
substanti
virtual
erad
diseas
mani
industri
countri
howev
optim
temper
trial
formalininactiv
respiratori
syncyti
viru
rsv
measl
vaccin
lead
enhanc
diseas
atyp
measl
rash
enhanc
pneumonia
bronchiol
bronchiti
experi
slow
progress
led
cautiou
approach
vaccin
develop
recent
histori
also
character
withdraw
appar
effect
vaccin
unaccept
side
effect
eg
vaccin
rotaviru
lyme
diseas
oral
live
attenu
adenoviru
vaccin
use
us
armi
recruit
sinc
elimin
frequent
epidem
traine
camp
manufactur
vaccin
ceas
product
outbreak
adenovir
respiratori
ill
reemerg
militari
set
develop
new
vaccin
adenoviru
infect
expens
exercis
virus
transmit
respiratori
gastrointestin
genit
rout
result
virtual
infect
propag
without
assist
bite
insect
respiratori
virus
remark
success
caus
substanti
morbid
mortal
part
world
serolog
distinct
virus
occupi
one
ecolog
nich
problemat
pathogen
chang
age
rsv
human
metapneumoviru
hmpv
parainfluenza
common
infanc
wherea
rhinoviru
influenza
predomin
older
elderli
person
season
mani
pathogen
make
difficult
plan
effici
econom
health
care
affect
patient
year
influenza
caus
excess
death
uk
approxim
death
person
age
year
older
influenza
death
increas
substanti
last
two
decad
larg
part
age
increasingli
dens
popul
rhinovirus
coronavirus
caus
common
cold
rel
littl
direct
mortal
although
sometim
consid
minor
nuisanc
may
infect
lower
respiratori
tract
caus
exacerb
chronic
bronchiti
asthma
effect
viral
diseas
infanc
exacerb
condit
prematur
cardiac
pulmonari
diseas
rsv
major
caus
infantil
hospit
infect
children
first
year
life
parainfluenza
account
approxim
respiratori
hospit
children
interestingli
parainfluenza
viru
peak
late
spring
summer
wherea
peak
occur
oneor
twoyearli
interv
late
autumn
earli
winter
adenoviru
caus
respiratori
diseas
children
younger
year
old
emerg
new
respiratori
pathogen
eg
sever
acut
respiratori
syndrom
sar
avian
influenza
littl
resist
particular
threat
human
health
prosper
global
allianc
area
respiratori
vaccin
support
million
donat
bill
melinda
gate
foundat
difficulti
develop
vaccin
work
target
popul
neonat
presenc
matern
antibodi
nonmatur
immun
system
major
challeng
elderli
immun
respons
tend
rel
weak
ineffect
rapid
rate
viral
mutat
presenc
differ
strain
year
togeth
fact
infect
one
strain
offer
substanti
immun
anoth
provid
key
challeng
advanc
vaccin
technolog
addit
specif
issu
emerg
pathogen
difficulti
predict
viral
strain
respond
rapidli
identifi
pandem
influenza
larg
quantiti
vaccin
would
requir
short
time
make
signific
impact
face
spread
epidem
could
kill
signific
proport
world
popul
month
time
requir
vaccin
product
novel
technolog
may
assist
acceler
vaccin
product
exampl
cell
cultur
could
suitabl
embryon
chicken
egg
howev
safeti
grow
larg
bulk
stock
lethal
virus
purif
inactiv
addit
concern
major
hurdl
rsv
vaccin
develop
possibl
enhanc
diseas
subsequ
natur
infect
formalininactiv
rsv
firsv
vaccin
tri
normal
children
vaccine
protect
moreov
becam
natur
infect
suffer
increas
rate
hospit
due
pneumonia
bronchiol
rhiniti
bronchiti
enhanc
clearli
caus
overexuber
immun
respons
exact
reason
effect
still
unclear
full
elucid
mechan
involv
vaccineenhanc
diseas
crucial
develop
futur
rsv
vaccin
new
vaccin
must
complet
safe
accord
precautionari
principl
possibl
side
effect
even
theoret
call
halt
develop
caus
vaccin
withdrawn
especi
true
vaccin
children
prevent
socal
trivial
diseas
cost
develop
singl
candid
vaccin
grow
per
year
approach
billion
novel
technolog
concept
expect
reduc
price
significantli
averag
take
year
make
new
vaccin
figur
ideal
vaccin
confer
longliv
protect
singl
dose
easi
manufactur
larg
scale
final
product
resist
extrem
temperatur
conveni
store
use
also
avail
combin
reduc
number
inject
need
effect
local
needlefre
administr
licens
vaccin
global
bypass
need
costli
local
approv
process
wide
use
effect
vaccin
respiratori
viral
infect
inactiv
purifi
subunit
influenza
vaccin
made
hemagglutinin
neuraminidas
protein
produc
current
circul
influenza
strain
composit
vaccin
decid
year
accord
exact
strain
like
caus
winter
influenza
determin
previou
spring
expert
intern
committe
influenza
isol
like
spread
global
select
expand
cultur
embron
egg
test
limit
immunogen
studi
human
volunt
differ
vaccin
prepar
test
efficaci
prevent
influenza
infect
symptom
vaccin
base
assumpt
induct
antibodi
necessari
suffici
protect
influenza
normal
vaccin
efficaci
strain
influenza
ineffect
emerg
mutant
strain
particular
problem
crossspeci
transmiss
avian
influenza
eg
spanish
influenza
strain
prevent
vaccin
import
prioriti
therefor
develop
new
method
vaccin
extend
specif
vaccin
give
least
protect
newli
emerg
strain
influenza
inactiv
vaccin
use
year
tend
associ
local
side
effect
tabl
live
attenu
vaccin
offer
signific
advantag
particularli
appli
mucos
highli
immunogen
induc
good
serum
antibodi
level
mucos
immunoglobulin
iga
cell
respons
coldadapt
live
influenza
vaccin
wide
evalu
us
japan
sinc
develop
continu
recent
live
attenu
coldadapt
influenza
viru
vaccin
found
effect
influenza
healthi
children
exampl
flumist
medimmun
avail
intranas
use
healthi
person
age
year
paradox
seem
protect
seen
absenc
serum
antibodi
circumst
challeng
view
antibodi
essenti
protect
attenu
coldpassag
rsv
vaccin
cptsrsv
cptsrsv
enter
clinic
trial
howev
insuffici
attenu
lead
otiti
media
attenu
cptsrsv
appear
safe
infecti
immunogen
seroneg
children
caus
upper
respiratori
tract
congest
young
infant
current
method
achiev
full
attenu
without
possibl
revers
virul
test
includ
delet
insert
entir
gene
clear
whether
genet
modifi
live
virus
accept
regulatori
author
public
purifi
rsv
glycoprotein
also
test
vaccin
candid
shown
induc
neutral
antibodi
effect
cotton
rat
appear
enhanc
pulmonari
patholog
clinic
trial
perform
f
protein
purifi
immunoaffin
chromatographi
rsvinfect
cell
lysat
test
seroposit
children
induc
eightfold
increas
serumneutr
antibodi
reduc
risk
subsequ
infect
studi
seroneg
infant
show
multipl
immun
requir
achiev
high
antibodi
titer
highli
purifi
prepar
test
children
suffer
bronchopulmonari
dysplasia
shown
safe
yet
clear
effect
formalininactiv
parainfluenza
vaccin
also
nonprotect
infect
liveattenu
coldadapt
vaccin
candid
undergo
test
exampl
shown
genet
stabl
safe
appropri
attenu
immunogen
even
infant
young
month
age
vaccin
genet
hybrid
bovin
human
coat
protein
test
vaccin
parainfluenza
reach
phase
ii
clinic
trial
test
month
old
infant
safeti
toler
infect
immunogen
human
metapneumoviru
human
metapneumoviru
hmpv
discov
ubiquit
least
year
part
globe
known
second
import
caus
respiratori
tract
infect
young
children
clinic
symptom
similar
rsv
coinfect
sometim
seen
possibl
lead
sever
diseas
rsv
hmpv
belong
famili
virus
paramyxovirida
vaccin
effect
virus
would
highli
desir
genet
hybrid
bovin
express
fusion
protein
hmpv
protect
immunogen
attenu
african
green
monkey
warrant
evalu
human
sever
acut
respiratori
syndrom
sever
acut
respiratori
syndrom
sar
spread
alarmingli
southeast
asia
rapidli
discov
coronaviru
sarscov
caus
probabl
wildcaught
anim
eg
via
civet
cat
high
mortal
rate
potenti
rapid
spread
gave
great
urgenc
convent
tabl
dna
vaccin
initi
tabl
rang
anim
model
use
test
singl
model
seem
ideal
one
particular
concern
possibl
enhanc
diseas
manner
similar
seen
formalininactiv
rsv
felin
periton
due
coronaviru
infect
cat
effect
alreadi
seen
murin
model
sar
sinc
sar
disappear
seem
unlik
opportun
aris
test
vaccin
efficaci
human
initi
report
came
asia
iav
found
caus
diseas
chicken
big
wild
anim
pet
cat
among
confirm
case
iav
infect
human
fatal
time
write
octob
infect
report
netherland
usa
hong
kong
canada
egypt
lead
fever
cough
andor
conjunct
progress
respiratori
failur
death
infect
person
major
problem
abil
identifi
correct
subtyp
scale
product
test
vaccin
stock
send
suppli
vaccin
time
signific
impact
worldwid
spread
figur
genet
engin
vaccin
recombin
dna
technolog
previous
describ
possibl
genet
engin
dna
viru
vector
creat
novel
rna
virus
revers
genet
therefor
feasibl
coexpress
cytokin
chemokin
host
caus
select
enhanc
certain
type
immun
may
protect
nonpathogen
reduc
reactiv
vaccin
lessen
chanc
diseas
augment
mutat
spontan
attenu
mutant
identifi
engin
intellig
knockout
live
vector
creat
long
term
may
possibl
understand
reason
pathogen
evad
immun
recognit
persist
understood
vaccin
abl
modifi
immun
respons
clear
persist
infect
may
becom
feasibl
inject
dna
encod
viral
antigen
confer
protect
immun
abl
condit
trigger
protect
immun
respons
figur
surpris
effect
seem
due
dna
uptak
antigenpres
cell
subsequ
protein
express
typic
respons
includ
cytotox
cell
case
good
antibodi
respons
dna
advantag
stabil
safeti
need
given
larg
quantiti
achiev
immunogen
current
much
interest
find
way
make
lower
quantiti
dna
immunogen
adjuv
deliv
dna
vaccin
use
gene
gun
mucos
administr
b
cell
figur
dna
vaccin
work
dna
vaccin
administ
intramuscularli
inject
gene
gun
target
myocyt
keratinocyt
insid
target
cell
specifi
antigen
express
use
dna
replic
materi
present
apc
directli
transfect
plasmid
target
cell
act
apc
directli
howev
major
evid
exist
secret
antigen
phagocytosisendocytosi
apc
present
via
either
major
histocompat
complex
mhc
class
class
ii
pathway
present
via
mhc
class
induc
cell
differenti
effector
memori
cell
capac
kill
virusinfect
cell
present
via
mhc
class
ii
induc
tcell
activ
turn
cell
known
helper
cell
function
promot
bcell
antibodi
product
surviv
via
stimul
interact
interleukin
secret
act
help
tcell
function
tcell
also
secret
multitud
cytokin
eg
interferon
gamma
ifng
consequ
immunoregulatori
effect
humor
respons
also
elicit
follow
antigen
encount
lead
pool
memori
b
cell
well
neutral
antibodi
product
pulmonari
arteri
hypertens
defin
mean
pulmonari
arteri
pressur
mmhg
exercis
pulmonari
arteri
hypertens
may
idiopath
famili
associ
condit
congenit
heart
diseas
liver
diseas
connect
tissu
diseas
pulmonari
arteri
hypertens
may
also
occur
ingest
appetit
suppress
drug
toxic
oil
histolog
sequenti
chang
smooth
muscl
hypertrophi
arteri
wall
intim
prolifer
situ
thrombosi
small
vessel
occlus
format
plexiform
lesion
crosssect
area
pulmonari
vascular
bed
diminish
sever
small
vessel
obliter
progress
sustain
elev
pulmonari
vascular
resist
lead
right
heart
insuffici
onset
symptom
clinic
cours
unremit
progress
right
heart
failur
death
last
decad
convent
therapi
limit
digoxin
diuret
calcium
channel
blocker
warfarin
anticoagul
median
surviv
year
howev
therapi
includ
prostacyclin
analog
deliv
intraven
subcutan
inhal
endothelin
receptor
blocker
bosentan
phosphodiesteras
type
inhibitor
sildenafil
continu
inhal
nitric
oxid
ga
pulmonari
venoocclus
diseas
form
pulmonari
arteri
hypertens
associ
signific
venou
involv
usual
idiopath
may
associ
malign
diseas
treatment
congenit
heart
diseas
autoimmun
diseas
pulmonari
venoocclus
diseas
difficult
treat
pulmonari
edema
may
exacerb
vasodil
earli
lung
transplant
current
treatment
pulmonari
arterioven
malform
character
abnorm
larg
commun
pulmonari
arteri
venou
system
physiolog
consequ
secondari
hypoxemia
caus
right
left
shunt
desatur
pulmonari
arteri
blood
pulmonari
vein
without
travers
pulmonari
vascular
alveolar
interfac
etiolog
pulmonari
arterioven
malform
may
idiopath
associ
hereditari
hemorrhag
telangiectasia
syndrom
oslerrenduweb
syndrom
patient
liver
diseas
associ
portal
hypertens
pulmonari
arterioven
malform
complic
cours
patient
complex
congenit
heart
diseas
receiv
palliat
superior
cavopulmonari
anastomosi
treatment
coil
embol
larg
malform
pulmonari
arteri
hypertens
pah
defin
mean
pulmonari
arteri
pressur
mmhg
mmhg
exercis
pah
may
idiopath
famili
associ
condit
congenit
heart
diseas
liver
diseas
connect
tissu
diseas
may
also
occur
ingest
appetit
suppress
drug
toxic
oil
histolog
sequenti
chang
smooth
muscl
hypertrophi
arteri
wall
intim
prolifer
situ
thrombosi
small
vessel
occlus
format
plexiform
lesion
crosssect
area
pulmonari
vascular
bed
diminish
sever
small
vessel
obliter
progress
sustain
elev
pulmonari
vascular
resist
lead
right
heart
insuffici
onset
symptom
clinic
cours
unremit
progress
right
heart
failur
death
last
decad
convent
therapi
limit
digoxin
diuret
calcium
channel
blocker
warfarin
anticoagul
median
surviv
year
howev
therapi
includ
prostacyclin
analog
deliv
intraven
subcutan
inhal
endothelin
receptor
blocker
bosentan
phosphodiesteras
type
inhibitor
sildenafil
continu
inhal
nitric
oxid
ga
earli
descript
pulmonari
hypertens
disord
histolog
e
von
romberg
describ
histolog
featur
pulmonari
sclerosi
dr
ayerza
describ
syndrom
chronic
cyanosi
dyspnea
polycythemia
associ
pulmonari
arteri
sclerosi
etiolog
diseas
obscur
obscur
attribut
syphili
brenner
observ
diseas
manifest
right
heart
failur
secondari
pulmonari
diseas
introduct
cardiac
catheter
allow
direct
measur
pulmonari
pressur
also
investig
function
state
pulmonari
vascular
bed
late
hypox
vasoconstrict
